Shenzhen Neptunus Interlong Bio-technique Company Limited Stock

Equities

8329

CNE100000775

Pharmaceuticals

Market Closed - Hong Kong S.E. 04:08:35 2024-04-19 am EDT 5-day change 1st Jan Change
0.158 HKD 0.00% Intraday chart for Shenzhen Neptunus Interlong Bio-technique Company Limited +2.60% -3.66%

Financials

Sales 2022 987M 136M 1.07B Sales 2023 1.06B 147M 1.15B Capitalization 250M 34.55M 271M
Net income 2022 54M 7.46M 58.42M Net income 2023 24M 3.32M 25.97M EV / Sales 2022 -
Net cash position 2022 257M 35.55M 278M Net cash position 2023 293M 40.4M 316M EV / Sales 2023 -0.04 x
P/E ratio 2022
4.69 x
P/E ratio 2023
10.4 x
Employees 1,444
Yield 2022 *
-
Yield 2023
-
Free-Float 25.13%
More Fundamentals * Assessed data
Dynamic Chart
Shenzhen Neptunus Interlong Bio-technique Company Limited Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Shenzhen Neptunus Interlong Bio-Technique Company Limited Provides Consolidated Earnings Guidance for the Year Ended 31 December 2023 CI
Shenzhen Neptunus Interlong Bio-Technique Company Limited Announces Change of Principal Place of Business CI
Shenzhen Neptunus Interlong Bio-technique Company Limited Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Shenzhen Neptunus Interlong Bio-technique Company Limited Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
Shenzhen Neptunus Interlong Bio-Technique Company Limited Announces Appointment of Executive Director and Retirement of Non-Executive Director CI
Shenzhen Neptunus Interlong Bio-technique Company Limited Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Shenzhen Neptunus Interlong Bio-Technique Company Limited Announces Change of Address of Registered Office CI
Shenzhen Neptunus Interlong Bio-technique Company Limited Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022 CI
Shenzhen Neptunus Interlong Bio-technique Company Limited Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022 CI
Shenzhen Neptunus Interlong Bio-technique Company Limited Reports Earnings Results for the First Quarter Ended March 31, 2022 CI
Shenzhen Neptunus Interlong Bio-Technique Company Limited Appoints Jin Rui as Non-Executive Director CI
Shenzhen Neptunus Interlong Bio-technique Company Limited Reports Earnings Results for the Full Year Ended December 31, 2021 CI
Shenzhen Neptunus Interlong Bio-technique Company Limited Announces the Demise of Xu Yan He, Non-Executive Director CI
Shenzhen Neptunus Interlong Bio-technique Company Limited Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021 CI
More news
1 week+2.60%
1 month-1.25%
3 months-0.63%
6 months+1.94%
Current year-3.66%
More quotes
1 week
0.15
Extreme 0.151
0.17
1 month
0.15
Extreme 0.15
0.17
Current year
0.14
Extreme 0.136
0.18
1 year
0.13
Extreme 0.133
0.18
3 years
0.12
Extreme 0.116
0.28
5 years
0.12
Extreme 0.116
1.29
10 years
0.12
Extreme 0.116
1.37
More quotes
Managers TitleAgeSince
Chairman 52 11-05-31
Director/Board Member 47 20-04-23
Corporate Secretary 41 20-05-31
Members of the board TitleAgeSince
Director/Board Member 47 20-04-23
Chairman 52 11-05-31
Director/Board Member 66 05-01-31
More insiders
Date Price Change Volume
24-04-19 0.158 0.00% 0
24-04-18 0.158 +2.60% 10,000
24-04-17 0.154 0.00% 40,000
24-04-16 0.154 0.00% 70,000
24-04-15 0.154 0.00% 10,000

Delayed Quote Hong Kong S.E., April 19, 2024 at 04:08 am EDT

More quotes
Shenzhen Neptunus Interlong Bio-Technique Company Limited is a Hong Kong-based company principally engaged in the development, production and sales of medicines. The Company operates through three segments. Medicines segment is engaged in the manufacture and sales of medicines. Medicines and Healthcare Products segment is engaged in the sales and distribution of medicines and healthcare products. Research and Development Services of Modern Biological Technology segment is engaged in the provision of research and development services of modern biological technologies, such as in vitro diagnostics reagents businesses. The products of the Company include herbal medicines, generic drugs, transfusion and anti-tumor drugs, among others. The Company mainly operates businesses in China.
More about the company

Annual profits - Rate of surprise